
The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.
Even President Emmanuel Macron is involved in the debate centred on a perceived "loss of sovereignty" if popular painkiller Doliprane falls into American hands.